Are people with cystic fibrosis eating too much salt?

  • Research type

    Research Study

  • Full title

    Are people with cystic fibrosis, treated with modulator medicines ingesting too much salt, putting them at increased risk of cardiovascular complications?

  • IRAS ID

    331581

  • Contact name

    Harriet Gledhill

  • Contact email

    harriet.gledhill@nhs.net

  • Sponsor organisation

    University of Plymouth

  • Duration of Study in the UK

    0 years, 3 months, 17 days

  • Research summary

    Cystic Fibrosis (CF) is a life limited genetic conditions, which is the result of the defective Cystic Fibrosis Transmembrane conductance regulator (CFTR) gene, disturbing the reabsorption of sodium and chloride in the mucus, leading to increased sodium losses in the sweat.
    In the standard of care for cystic fibrosis, there is a lack of evidence to determine what constitutes the correct sodium supplementation and currently the focus is on avoiding symptoms related to sodium depletion.
    However with the recent introduction of the new CFTR modulator medication, there is an improvement in the function of the sodium chloride channels. This is along side a now ageing cystic fibrosis population that is experiencing more co-mobility’s, some of which have important modifiable factor, such as hypertension.
    This retrospective cohort research will aim to address the hypothesis that: People with Cystic Fibrosis treated with modulator medicines are excreting too much sodium, which leads to the hypothesis that they are ingesting too much sodium and increasing their risk of hypertension and its complications, a situation which can be remediated by dietary intervention.

    The aim of this research study is to identify:
    • What proportion of people with cystic fibrosis have an excessive sodium excretion, after starting on a CFTR modulator?

    It is anticipated that these results will inform a further study, to ensure that the risk of excessive sodium intakes are addressed, thereby reducing the possible risk of hypertension and its associated complications.

  • REC name

    Wales REC 7

  • REC reference

    25/WA/0209

  • Date of REC Opinion

    15 Jul 2025

  • REC opinion

    Favourable Opinion